Search research articles
Contact Us
Filters
Showing results (61-70 of 105) with videos related to
Page
of 11
Sort By:
Nature Communications
|
July 8, 2022
PRMT5 activates AKT via methylation to promote tumor metastasis
Lei Huang, Xiao-Ou Zhang, Esteban J Rozen, et al.
European Urology Focus
|
November 11, 2020
Clinical Trial Protocol for LuTectomy: A Single-arm Study of the Dosimetry, Safety, and Potential Benefit of <sup>177</sup>Lu-PSMA-617 Prior to Prostatectomy
Nattakorn Dhiantravan, John Violet, Renu Eapen, et al.
Contemporary Clinical Trials Communications
|
May 11, 2023
NeoAdjuvant pembrolizumab and STEreotactic radiotherapy prior to nephrectomy for renal cell carcinoma (NAPSTER): A phase II randomised clinical trial
Muhammad Ali, Simon Wood, David Pryor, et al.
European Urology
|
March 28, 2025
A Comprehensive Systematic Review and Meta-analysis of the Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Diagnosis and Primary Staging before Definitive Treatment
Elio Mazzone, Donato Cannoletta, Leonardo Quarta, et al.
European Urology
|
May 20, 2025
The Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Assessment of Local Recurrence and Distant Metastases in Patients with Biochemical Recurrence of Prostate Cancer After Definitive Treatment: A Systematic Review and Meta-analysis
Elio Mazzone, Alice Thomson, David C Chen, et al.
European Urology Open Science
|
July 13, 2023
A Novel Risk Calculator Incorporating Clinical Parameters, Multiparametric Magnetic Resonance Imaging, and Prostate-Specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Risk Stratification Before Transperineal Prostate Biopsy
Brian D Kelly, Gideon Ptasznik, Matthew J Roberts, et al.
BJU International
|
November 13, 2022
Synchronous vs independent reading of prostate-specific membrane antigen positron emission tomography (PSMA-PET) and magnetic resonance imaging (MRI) to improve diagnosis of prostate cancer
Paul Doan, William Counter, Nathan Papa, et al.
Contemporary Clinical Trials Communications
|
January 25, 2021
A phase I/II study of stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumours (RAPPORT): Clinical trial protocol
David Pryor, Mathias Bressel, Nathan Lawrentschuk, et al.
Cancers
|
March 28, 2026
Quality and Usability of Prostate Cancer Information Generated by Artificial Intelligence Chatbots: A Comparative Analysis
Abdullah Al-Khanaty, Jordan Santucci, David Hennes, et al.
International Journal of Cancer
|
June 15, 2019
Fractionated stereotactic body radiotherapy for up to five prostate cancer oligometastases: Interim outcomes of a prospective clinical trial
Patrick Bowden, Andrew W See, Mark Frydenberg, et al.
Page
of 11
Search research articles
Search
Showing results (61-70 of 105) with videos related to
Sort By:
Page
of 11
Nature Communications
|
July 8, 2022
PRMT5 activates AKT via methylation to promote tumor metastasis
Lei Huang, Xiao-Ou Zhang, Esteban J Rozen, et al.
European Urology Focus
|
November 11, 2020
Clinical Trial Protocol for LuTectomy: A Single-arm Study of the Dosimetry, Safety, and Potential Benefit of <sup>177</sup>Lu-PSMA-617 Prior to Prostatectomy
Nattakorn Dhiantravan, John Violet, Renu Eapen, et al.
Contemporary Clinical Trials Communications
|
May 11, 2023
NeoAdjuvant pembrolizumab and STEreotactic radiotherapy prior to nephrectomy for renal cell carcinoma (NAPSTER): A phase II randomised clinical trial
Muhammad Ali, Simon Wood, David Pryor, et al.
European Urology
|
March 28, 2025
A Comprehensive Systematic Review and Meta-analysis of the Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Diagnosis and Primary Staging before Definitive Treatment
Elio Mazzone, Donato Cannoletta, Leonardo Quarta, et al.
European Urology
|
May 20, 2025
The Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Assessment of Local Recurrence and Distant Metastases in Patients with Biochemical Recurrence of Prostate Cancer After Definitive Treatment: A Systematic Review and Meta-analysis
Elio Mazzone, Alice Thomson, David C Chen, et al.
European Urology Open Science
|
July 13, 2023
A Novel Risk Calculator Incorporating Clinical Parameters, Multiparametric Magnetic Resonance Imaging, and Prostate-Specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Risk Stratification Before Transperineal Prostate Biopsy
Brian D Kelly, Gideon Ptasznik, Matthew J Roberts, et al.
BJU International
|
November 13, 2022
Synchronous vs independent reading of prostate-specific membrane antigen positron emission tomography (PSMA-PET) and magnetic resonance imaging (MRI) to improve diagnosis of prostate cancer
Paul Doan, William Counter, Nathan Papa, et al.
Contemporary Clinical Trials Communications
|
January 25, 2021
A phase I/II study of stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumours (RAPPORT): Clinical trial protocol
David Pryor, Mathias Bressel, Nathan Lawrentschuk, et al.
Cancers
|
March 28, 2026
Quality and Usability of Prostate Cancer Information Generated by Artificial Intelligence Chatbots: A Comparative Analysis
Abdullah Al-Khanaty, Jordan Santucci, David Hennes, et al.
International Journal of Cancer
|
June 15, 2019
Fractionated stereotactic body radiotherapy for up to five prostate cancer oligometastases: Interim outcomes of a prospective clinical trial
Patrick Bowden, Andrew W See, Mark Frydenberg, et al.
Page
of 11